As of November 14, 2026, Sonoma Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 2, 2026 to January 28, 2026, naming 1 appointment and 1 departure. The latest filing names Jay Birnbaum, leaving (Form 8-K, January 28, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Sonoma Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Sonoma Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-02 to 2026-01-28. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Sonoma Pharmaceuticals, Inc. files it.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-01-28 | Out | 2026-01-28 | 8-K, 2026-01-28 | ||
| 2026-01-28 | In | Director | 2026-01-28 | 8-K, 2026-01-28 | |
| 2026-01-02 | Reported | not named in the filing | 8-K, 2026-01-02 |
Selling to them or working with them? See who runs Sonoma Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Watch Sonoma Pharmaceuticals, Inc.
Get an email when Sonoma Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sonoma Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Sonoma Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sonoma Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Jay Birnbaum (filed 2026-01-28):
Retirement of Director Effective January 28, 2026, Dr. Jay Birnbaum retired from our Board of Directors.
Who leads Sonoma Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Vanessa Jacoby, appointed, effective 2026-01-28 (filed 2026-01-28).
New leaders reset buying decisions — get the Full Report on Sonoma Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Sonoma Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at Sonoma Pharmaceuticals, Inc.Every change, in the filing's words
Departing: Jay Birnbaum, effective 2026-01-28
Effective January 28, 2026, Dr. Jay Birnbaum retired from our Board of Directors.
Appointed: Vanessa Jacoby, Director, effective 2026-01-28
Effective January 28, 2026, our Board appointed Ms. Vanessa Jacoby as a director of our Company.
- Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Dr. Birnbaum has served on our Board since April 2007.
- We are grateful for his many years of services and the valuable knowledge he has provided to our Company.
- Dr. Birnbaum will continue to serve the Company pursuant to a consulting agreement (the "Consulting Agreement"), for a term of one year.
- Dr. Birnbaum will receive compensation of 5,000 Restricted Stock Units (RSUs) representing 5,000 shares of the Company's Common Stock per quarter.
- Such RSUs will vest on the second business day after Sonoma files its Annual Report on Form 10-K for the year ended March 31, 2027, or upon change of control.
- Any outstanding equity awards held by Dr. Birnbaum will continue to vest in accordance with their terms, subject to Dr. Birnbaum's continued compliance with the terms of the Consulting Agreement through each applicable vesting date.
Reported
Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- On January 2, 2026, we completed our annual equity grant to employees, including executive officers, of the Company.
- The annual grant is intended to recognize employees who meet certain employment criteria and to retain key employees.
- The Company's non-employee directors each received 10,000 options.
- The exercise price of the options is based on the closing price of our common stock of $3.68 per share on January 2, 2026, and the options vest in three equal tranches on the first, second and third anniversary of the grant date.
- Each executive officer received Restricted Stock Units (RSUs) as follows: Amy Trombly, Chief Executive Officer: 10,000 RSUs; and Jerry Dvonch, Chief Financial Officer: 5,000 RSUs.
Tools for this story
Each opens in a new tab, filled in for Sonoma Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
